Ordering Recommendation

Use to identify alcohol abuse or abuse relapse and detect chronic ethanol use (≥40 g/day for 2 weeks). For evaluation of patients suspected of having congenital glycosylation disorder, refer to Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation (CDG) (2002918).

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube or plain red.

Specimen Preparation

Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL)

Storage/Transport Temperature

Frozen.

Unacceptable Conditions

Plasma. Hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: Unacceptable; Refrigerated: 10 days; Frozen: 1 month

Methodology

Quantitative Electrophoresis

Performed

Thu

Reported

1-8 days

Reference Interval

Effective May 16, 2011

Normal 0-1.3%
Inconclusive 1.4-1.6%
Elevated Greater than or equal to 1.7%

Interpretive Data



Compliance Category

FDA

Note

This assay can detect chronic ethanol use (greater than 40 g/day for two weeks).

Hotline History

N/A

CPT Codes

82373

Components

Component Test Code* Component Chart Name LOINC
0070412 CDT for Alcohol Use 48495-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Alcohol consumption bio-marker
  • CDT
  • CDT for alcohol use
  • CDT, alcohol use
  • Serum Carbohydrate Deficient Transferrin, alcohol use
  • Transferrin
Carbohydrate Deficient Transferrin for Alcohol Use